

Semler Scientific, Inc.  
Form 8-K  
October 14, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 12, 2016**

**SEMLER SCIENTIFIC, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-36305**

**26-1367393**

Edgar Filing: Semler Scientific, Inc. - Form 8-K

(State or other jurisdiction of  
incorporation) (Commission File Number) (IRS Employer Identification No.)

**2330 NW Everett St.**

**97210**

**Portland, Oregon**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(877) 774-4211**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 12, 2016, Greg S. Garfield, a member of Class I of the Board of Directors of Semler Scientific, Inc. (the “*Board*”), notified the Board of his resignation from the Board, including from its Compensation Committee and Nominating Committee, effective as of October 12, 2016. Mr. Garfield’s decision to resign did not involve any disagreement with Semler Scientific, Inc., its management or the Board.

The Board accepted Mr. Garfield’s resignation and in connection therewith, effective October 13, 2016, reduced the size of the Board from eight to seven members, and the size of Class I from three to two members. The Board also appointed, upon the recommendation of the sole remaining member of the Nominating Committee, current director, Dr. Abbie Leibowitz, to fill the vacancies on the Compensation Committee and Nominating Committee created by Mr. Garfield’s departure.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEMLER SCIENTIFIC, INC.**

By: /s/ Douglas Murphy-Chutorian  
Name: Douglas Murphy-Chutorian  
Title: Chief Executive Officer

Date: October 14, 2016